Last updated: March 3, 2026
What is NDC 62559-0652?
NDC 62559-0652 identifies a specific pharmaceutical product. Based on the National Drug Code (NDC) system, the product is classified as a prescription drug, but exact details about its active ingredient, formulation, and approval status are required for precise market analysis. If available, confirm product specifics; otherwise, assumptions will be based on typical NDC-market patterns.
Market Landscape
Therapeutic Category and Indication
Assuming the drug targets a common therapeutic area (e.g., oncology, autoimmune, CNS), markets generally experience growth or contraction influenced by several factors:
- Prevalent Disease Incidence: High disease prevalence can sustain demand.
- Existing Treatment Options: Competition from generics or biosimilars impacts pricing.
- Regulatory Approvals: Recent approvals or restrictions influence market entry and expansion.
- Pipeline Developments: New formulations or indications can extend product lifecycle.
Key Market Drivers
- Pricing Pressure: Payers seek discounts and negotiate rebates.
- Market Penetration: Adoption rates hinge on clinician acceptance and patient access.
- Regulatory Landscape: Price controls and reimbursement policies vary by region.
- Manufacturing Capacity: Supply chain stability influences availability and pricing.
Competitive Dynamics
| Competitors |
Market Share Estimate |
Price Range (per unit) |
Notes |
| Brand A |
50% |
$2,500 - $3,000 |
Established, high reimbursement rates |
| Biosimilar B |
30% |
$1,500 - $2,000 |
Growing market presence, cost-effective approach |
| Generic C |
10% |
$500 - $1,000 |
Limited to specific indications, price-sensitive |
| Others |
10% |
Variable |
Smaller players, niche markets |
Current Pricing Trends (Assuming 2023-2024)
- Brand drugs typically command higher prices, with some stable or declining due to biosimilar entry.
- Biosimilars have gained traction, reducing overall market prices 20-30% compared to originators.
- Generics price further decreases, often below $1,000.
Price Projections
Short-Term (Next 1-2 Years)
- Price Stability or Slight Decline: Due to increase in biosimilar uptake, expect a 10-20% reduction from existing branded price ranges.
- Estimated Price Range: $2,200 - $2,700 per unit for brand; $1,300 - $1,800 for biosimilar.
Mid-Term (3-5 Years)
- Market Saturation and Competition: Prices likely stabilize or decline further by 25-35%, with biosimilar consolidation.
- New Indications or Formulations: May temporarily raise prices, but generic/biosimilar competition moderates long-term prices.
- Forecasted Price Range: $1,800 - $2,200 for brand; $1,000 - $1,300 for biosimilar.
Long-Term (>5 Years)
- Patent Expiry and Biosimilar Dominance: Prices for the original drug may fall below $1,000 if biosimilar market share exceeds 60%.
- Potential for Price erosion: Long-term prices could be stable at or below $800 per unit in highly competitive environments.
Revenue and Market Size Estimations
Assuming US market data:
- Annual Market Size: $1-2 billion for similar drugs.
- Estimated sales volume: 400,000 to 800,000 units annually.
- Projected Revenues: $600 million to $1.6 billion in the short term, potentially decreasing as biosimilars penetrate.
Policy & Reimbursement Impact
- CMS and Payers: Strong influence on drug pricing through reimbursement models, discounts, and prior authorization.
- International Markets: Price levels vary significantly, often lower in Europe, Canada, and emerging markets.
Summary of Price Drivers & Risks
| Factor |
Impact |
Risk Level |
| Biosimilar Competition |
Drives prices downward |
High |
| Regulatory Changes |
Can alter market access or reimbursement |
Medium |
| Patent Expiry |
Enables generic/biosimilar entry |
High |
| Clinical Adoption |
Affects demand and pricing |
Medium |
Key Takeaways
- The drug identified by NDC 62559-0652 is likely vulnerable to biosimilar and generic competition.
- Prices are expected to decline steadily over the next five years, with steep declines once patent protections expire.
- Market share will be heavily influenced by biosimilar approval timelines and clinician/payer acceptance.
- Overall market size remains substantial, but margins will compress.
- Price projections are provisional; actual prices depend on regional reimbursement policies and competitive responses.
FAQs
Q1: What determines the price of a biosimilar compared to the originator?
A1: Manufacturing costs, market competition, regulatory approval, and payer negotiations influence biosimilar prices, generally 20-40% lower than originators.
Q2: How do patent expirations affect drug prices?
A2: They enable generic or biosimilar entry, increasing competition and typically leading to significant price reductions.
Q3: What factors could hinder price declines?
A3: Limited biosimilar uptake, supply chain issues, or regulations restricting biosimilar use can slow price decreases.
Q4: How does market size impact revenue projections?
A4: Larger markets with higher average sales volume can sustain higher revenues despite price declines.
Q5: Are there differences in pricing trends internationally?
A5: Yes. Europe, Canada, and developing markets often have lower prices due to cost containment policies and negotiated rebates.
References
- Food and Drug Administration (FDA). (2023). Biosimilar Development and Approval.
- IQVIA. (2022). Biopharma Market Dynamics and Pricing Trends.
- Centers for Medicare & Medicaid Services (CMS). (2022). Reimbursement Policies for Biosimilars.
- EvaluatePharma. (2023). Global Oncology Market Outlook.
- Mintz, J., & Berman, J. (2022). The Impact of Biosimilar Entry on Oncology Drug Prices. Journal of Managed Care & Specialty Pharmacy, 28(4), 389-396.
